<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Aim:</bold> Data on the use of novel anticoagulant drugs (NOACc) in renal transplant recipients is scarce. The aim of our study was to investigate the safety and efficacy of NOACs in renal transplant recipients.<bold>Materials and Methods:</bold> In a single-centre retrospective cohort study we assessed adverse reactions, thromboembolic events, and interactions of calcineurin inhibitors in patients treated with NOACs.<bold>Results</bold>: Twenty-three renal transplant recipients were treated with NOACs (70% male), mean age of 65.8 ± 1.8 years. Fourteen (61%) patients were treated with rivaroxaban, apixaban was given to 8 (35%) of our patients, and dabigatran to one patient (4%). The main indications for NOAC therapy was atrial fibrillation in 61% and deep venous thrombosis in 23% of patients. Bleeding occurred in 2 patients (1 treated with rivaroxaban and 1 with dabigatran). None of our patients developed thrombosis while treated with NOAC. During the median follow-up of 24 months graft function, as well as hematological parameters, remained stable in patients that were treated with rivaroxaban and apixaban, while dabigatran was ceased after a month of therapy due to a bleeding event.<bold>Conclusion</bold>: Our results show that both rivaroxaban and apixaban are safe and efficient oral anticoagulant drugs in renal transplant patients. Additional studies are needed to prove these results.</abstract>

Aim: Data on the use of novel anticoagulant drugs (NOACc) in renal transplant recipients is scarce. The aim of our study was to investigate the safety and efficacy of NOACs in renal transplant recipients.Materials and Methods: In a single-centre retrospective cohort study we assessed adverse reactions, thromboembolic events, and interactions of calcineurin inhibitors in patients treated with NOACs.Results: Twenty-three renal transplant recipients were treated with NOACs (70% male), mean age of 65.8 ± 1.8 years. Fourteen (61%) patients were treated with rivaroxaban, apixaban was given to 8 (35%) of our patients, and dabigatran to one patient (4%). The main indications for NOAC therapy was atrial fibrillation in 61% and deep venous thrombosis in 23% of patients. Bleeding occurred in 2 patients (1 treated with rivaroxaban and 1 with dabigatran). None of our patients developed thrombosis while treated with NOAC. During the median follow-up of 24 months graft function, as well as hematological parameters, remained stable in patients that were treated with rivaroxaban and apixaban, while dabigatran was ceased after a month of therapy due to a bleeding event.Conclusion: Our results show that both rivaroxaban and apixaban are safe and efficient oral anticoagulant drugs in renal transplant patients. Additional studies are needed to prove these results.

Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study

Department of nephrology, arterial hypertension, dialysis and transplantation

PRILOZI

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Aim: Data on the use of novel anticoagulant drugs (NOACc) in renal transplant recipients is scarce. The aim of our study was to investigate the safety and...

Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study

Pubblicato online: 02 ott 2020

Pagine: 49 - 55

DOI: https://doi.org/10.2478/prilozi-2020-0032

Parole chiave
novel anticoagulant drugs, rivaroxaban, apixaban, dabigatran, renal transplantation

© 2020 Nikolina Basic-Jukic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study

Pubblicato online: 02 ott 2020

Pagine: 49 - 55

DOI: https://doi.org/10.2478/prilozi-2020-0032

Parole chiavenovel anticoagulant drugs, rivaroxaban, apixaban, dabigatran, renal transplantation

© 2020 Nikolina Basic-Jukic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
novel anticoagulant drugs, rivaroxaban, apixaban, dabigatran, renal transplantation